Home › NDC Lookup › Ingredients › Metformin Hydrochloride › 71335-0889-03
Metformin Hydrochloride Extended Release 750 mg Tablet, Extended Release, 60-count — NDC 71335-0889-03 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Metformin Hydrochloride Extended Release 750 mg Tablet, Extended Release, 60-count — NDC 71335-0889-3 (Billing 71335-0889-03)

by Bryant Ranch Prepack · 60 TABLET, EXTENDED RELEASE in 1 BOTTLE

This is a package of 60 tablets of Metformin Hydrochloride Extended Release 750 mg Tablet, Extended Release from Bryant Ranch Prepack, no longer marketed (first marketed May 2016), no longer in the FDA NDC Directory.

NDC 71335-0889-03
🏷️ FDA NDC (as labeled) 71335-0889-3 billing pads the package segment with a zero
This package
Contains60-count Pack sizes5 compare ↓
Also priced by: Part D plans $0.1129/unit — full pricing hub ↓
Product page 71335-0889-01 Also comes in: 30 tablets 71335-0889-1 90 tablets 71335-0889-2 100 tablets 71335-0889-5 180 tablets 71335-0889-4
Rx only Generic Discontinued Non-controlled ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Metformin Hydrochloride (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0328-2025
Class II · Feb 25, 2025 — Presence of Foreign Tablets/Capsules. (A-S Medication Solutions LLC) · FDA recall D-0292-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Feb 2022. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 71335-0889-3
Product NDC 71335-0889
11-digit billing NDC 71335088903
RxCUI 860981
UNII 786Z46389E
Application # ANDA090295
SPL Set ID d7c1ff9e-4faa-4f65-9c87-e8108499791f
Established class (EPC) Biguanide
Chemical class Biguanides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Feb 2022)
Marketing start 2016-05-12
Route ORAL
Dosage form TABLET, EXTENDED RELEASE
Substance METFORMIN HYDROCHLORIDE
TE code (Orange Book) AB · RLD · RS
Quick answers
  • RxCUI (RxNorm): 860981
Why two NDCs? The FDA registers this code as 71335-0889-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 71335-0889-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Biguanide class.

Pharmacologic class Biguanide
Drug family (ATC) Biguanides
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📗 Our plain-language guide HelloPharmacist
  • Metformin works in three ways: it lowers the amount of sugar your liver dumps into your bloodstream, slows how much sugar your gut absorbs from food, and helps your body respond to...
  • What exactly is metformin doing for my diabetes?
  • Yes, this is very common — diarrhea, nausea, and stomach discomfort are the most frequently reported side effects, and they're often worst when you first start or when your dose go...
  • My stomach has been a mess since I started metformin. Is that normal? Will it get better?
📖 Read our full Metformin guide →
4
Nutrient depletion considerations

Metformin Hydrochloride may be associated with lower levels of 4 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Metformin Hydrochloride nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.1129 $6.77 / 60 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
71335-0889-01 71335-0889-1 Main listing 30 TABLET, EXTENDED RELEASE in 1 BOTTLE 2022-03-16 — Discontinued by firm
71335-0889-02 71335-0889-2 90 TABLET, EXTENDED RELEASE in 1 BOTTLE 2022-03-16 — Discontinued by firm
71335-0889-03 You're viewing this 60 TABLET, EXTENDED RELEASE in 1 BOTTLE 2022-03-16 — Discontinued by firm
71335-0889-04 71335-0889-4 180 TABLET, EXTENDED RELEASE in 1 BOTTLE 2022-03-16 — Discontinued by firm
71335-0889-05 71335-0889-5 100 TABLET, EXTENDED RELEASE in 1 BOTTLE 2022-03-16 — Discontinued by firm

You're viewing one of 5 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 60-count package — 60 tablet, extended release in 1 bottle.
How does this package differ from NDC 71335-0889-01?
Both are Metformin Hydrochloride Extended Release 750 mg Tablet, Extended Release — the drug itself is identical. This page's package is the 60-count one, while NDC 71335-0889-01 is the 30 tablets package.
What NDC number is used to bill for this package of Metformin Hydrochloride Extended Release 750 mg Tablet, Extended Release?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Metformin Hydrochloride 750 mg 29300-0399-01 Unichem 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 42385-0978-01 Laurus 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 42806-0633-01 Epic 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride Extended Release 750 mg 49483-0624-01 TIME 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 50268-0551-15 AvPAK 1 tablet $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 67877-0414-01 Ascend 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 68094-0804-50 Precision 100 tablets $0.053 AB Availability likely —
Metformin 750 mg 70010-0492-01 Granules 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 72578-0036-01 Viona 100 tablets $0.053 AB Availability likely —
Metformin hydrochloride ER 750 mg 76385-0129-01 UNICHEM 100 tablets $0.053 AB Availability likely —
Metformin ER 750 mg 82009-0118-01 Quallent 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 82009-0181-01 Quallent 100 tablets $0.053 AB Availability likely —
Metformin Hydrochloride 750 mg 62756-0143-01 Sun 100 tablets $0.054 — Discontinued —
Metformin hydrochloride 750 mg 33342-0240-11 Macleods 100 tablets $0.067 AB FDA listed —
Metformin Hydrochloride 750 mg 51224-0107-50 TAGI 100 tablets $0.067 AB FDA listed —
Metformin Hydrochloride 750 mg 10135-0824-05 Marlex 500 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 25000-0102-03 MARKSANS 30 tablets — AB FDA listed —
Metformin hydrochloride ER 750 mg 42291-0824-10 AvKARE 1000 tablets — AB FDA listed —
Metformin Hydrochloride Extended Release 750 mg 43063-0902-30 PD-Rx 30 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 50090-5246-00 A-S 90 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 50090-6839-00 A-S 90 tablets — AB FDA listed —
Metformin 750 mg 50090-7372-00 A-S 90 tablets — AB FDA listed —
Metformin 750 mg 50090-7373-00 A-S 90 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 50090-7534-00 A-S 90 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 50090-7535-00 A-S 90 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 51655-0077-26 Northwind 90 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 51655-0368-52 Northwind 30 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 59651-0549-01 Aurobindo 100 tablets — AB FDA listed —
Metformin ER 750 mg 62207-0492-40 Granules 3500 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 63629-9147-01 Bryant 100 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 65162-0179-03 Amneal 30 tablets — — FDA listed —
Metformin Hydrochloride 750 mg 65841-0039-01 Zydus 100 tablets — AB Discontinued —
Metformin Hydrochloride 750 mg 67046-1556-03 Coupler 30 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 68788-7205-01 Preferred 100 tablets — AB Discontinued —
Metformin Hydrochloride 750 mg 69238-2126-01 Amneal 100 tablets — — FDA listed —
Metformin Hydrochloride 750 mg 70518-2709-00 REMEDYREPACK 30 tablets — AB Discontinued —
Metformin Hydrochloride 750 mg 70518-4163-00 REMEDYREPACK 30 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 71205-0141-00 Proficient 100 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 71335-0776-01 Bryant 30 tablets — AB FDA listed —
Metformin Hydrochloride Extended Release 750 mgthis 71335-0889-03 Bryant 60 tablets — AB Discontinued —
Metformin Hydrochloride 750 mg 71335-2504-01 Bryant 30 tablets — AB FDA listed —
Metformin 750 mg 71335-2524-01 Bryant 30 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 71335-9752-01 Bryant 30 tablets — AB FDA listed —
Metformin hydrochloride ER 750 mg 71610-0666-60 Aphena 90 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 71610-0740-53 Aphena 60 tablets — — FDA listed —
Metformin hydrochloride ER 750 mg 71610-0867-53 Aphena 60 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 72162-1293-01 Bryant 100 tablets — AB FDA listed —
Metformin hydrochloride ER 750 mg 72789-0106-01 PD-Rx 100 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 72789-0451-30 PD-Rx 30 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 72789-0472-01 PD-Rx 100 tablets — AB FDA listed —
Metformin Hydrochloride 750 mg 72789-0548-93 PD-Rx 180 tablets — AB FDA listed —
Metformin Hydrochloride Extended Release 750 mg 82804-0148-00 Proficient 100 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2016
On the market since
May 2016
📍
2026
Currently FDA-listed
10 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeCapsule
Imprint102
Size19 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII B1QE5P712K
    Hypromellose 2208 is a plant-derived thickening agent that dissolves in water. It's used as a binder to help hold tablet ingredients together and as a coating on pills to control how quickly the medicine releases in your body.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.

3 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBryant Ranch Prepack
Application holderMARKSANS PHARMA LTD
FDA applicationANDA090295 (ANDA)
Labeler code71335
First marketedMay 2016
Product typeHuman Prescription Drug
Portfolio4,436 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 How Supplied / Storage and Handling 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 25 words ▾

Metformin Hydrochloride Extended-Release Tablets, USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

⏱️ Dosage and Administration ~3 min read ▾

There is no fixed dosage regimen for the management of hyperglycemia in patients with type 2 diabetes with metformin hydrochloride extended-release tablets or any other pharmacologic agent. Dosage of metformin hydrochloride extended-release tablets must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The maximum recommended daily dose of metformin hydrochloride extended-release tablets in adults is 2000 mg.

Metformin hydrochloride extended-release tablets should generally be given once daily with the evening meal. Metformin hydrochloride extended-release tablets should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient. During treatment initiation and dose titration (see Recommended Dosing Schedule), fasting plasma glucose should be used to determine the therapeutic response to metformin hydrochloride extended-release tablets and identify the minimum effective dose for the patient.

Thereafter, glycosylated hemoglobin should be measured at intervals of approximately three months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of metformin hydrochloride extended-release tablets, either when used as monotherapy or in combination with sulfonylurea or insulin. Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness.

Short-term administration of metformin hydrochloride extended-release tablets may be sufficient during periods of transient loss of control in patients usually well-controlled on diet alone. Metformin hydrochloride extended-release tablets must be swallowed whole and never crushed or chewed. Occasionally, the inactive ingredients of metformin hydrochloride extended-release tablets will be eliminated in the feces as a soft, hydrated mass.

(See Patient information printed below.) Recommended Dosing Schedule Adults - In general, clinically significant responses are not seen at doses below 1500 mg per day. However, a lower recommended starting dose and gradually increased dosage is advised to minimize gastrointestinal symptoms. The usual starting dose of metformin hydrochloride extended-release tablet is 500 mg once daily with the evening meal.

Dosage increases should be made in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal. If glycemic control is not achieved on metformin hydrochloride extended-release tablets 2000 mg once daily, a trial of metformin hydrochloride extended-release tablets 1000 mg twice daily should be considered. In a randomized trial, patients currently treated with metformin hydrochloride tablets were switched to metformin hydrochloride extended-release tablets.

Results of this trial suggest that patients receiving metformin hydrochloride tablets treatment may be safely switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2000 mg once daily. Following a switch from metformin hydrochloride tablets to metformin hydrochloride extended-release tablets, glycemic control should be closely monitored and dosage adjustments made accordingly Pediatrics – Safety and effectiveness of metformin hydrochloride extended-release tablets in pediatric patients have not been established.

Transfer From Other Antidiabetic Therapy When transferring patients from standard oral hypoglycemic agents other than chlorpropamide to metformin hydrochloride extended-release tablets, no transition period generally is necessary. When transferring… [Excerpted — this section continues on DailyMed.]

⚠️ Warnings 176 words ▾

WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin­ associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin­associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL (see PRECAUTIONS).

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and PRECAUTIONS).

If metformin-associated lactic acidosis is suspected, immediately discontinue metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended (see PRECAUTIONS).

📦 How Supplied / Storage and Handling 96 words ▾

HOW SUPPLIED Metformin Hydrochloride Extended-Release Tablets, USP 750 mg are white to off-white, capsule shaped, biconvex tablets, debossed with '102' on one side and plain on other side. NDC: 71335-0889-1: 30 Tablets in a BOTTLE NDC: 71335-0889-2: 90 Tablets in a BOTTLE NDC: 71335-0889-3: 60 Tablets in a BOTTLE NDC: 71335-0889-4: 180 Tablets in a BOTTLE NDC: 71335-0889-5: 100 Tablets in a BOTTLE Storage Store at 20°–25° C (68°–77° F); excursions permitted to 15°–30° C (59°–86° F). [See USP Controlled Room Temperature.] Dispense in a light-resistant container.

Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

📄 Package Label / Principal Display Panel 5 words ▾

Metformin ER 750mg Tablet Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 4 other package presentations of this same product, including 30 tablets (71335-0889-01), 90 tablets (71335-0889-02), 100 tablets (71335-0889-05). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Bryant Ranch Prepack is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 71335-0886-01 · Bryant 71335-0890-01 · Bryant →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.